Paradoxical bronchospasm: A potentially life threatening adverse effect of albuterol

Southern Medical Journal

Volumn 99, Issue 3, 2006, Pages 288-289

  Raghunathan, Kalpana ^a,b   Nagajothi, Nagapradeep ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

Albuterol; Levalbuterol; Paradoxical bronchospasm

Indexed keywords

LEVALBUTEROL; SALBUTAMOL;

AGED; ARTICLE; ASTHMA; BRONCHOSPASM; CASE REPORT; DISEASE COURSE; DRUG SOLUTION; DRUG WITHDRAWAL; HUMAN; MALE; PARADOXICAL DRUG REACTION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED, 80 AND OVER; ALBUTEROL; BRONCHIAL SPASM; BRONCHODILATOR AGENTS; EPINEPHRINE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYMPATHOMIMETICS;

EID: 33645100656     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000202699.93002.e8     Document Type: Article

References (5)

1. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol:efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003;123:128-135.
2. Package insert for Xopenex. In: Physicians Desk Reference. Montvale, Medical Economics Company, 2002, pp 3207-3209.
3. Yarbrough J, Mansfield L, Ting S. Metered dose induced bronchospasm in asthmatic patients. Ann Allergy 1985;55:25-27.
4. Perrin-Fayolle M. Salbutamol in the treatment of asthma [letter]. Lancet 1995;346:1101.
5. American Academy of Pediatrics Committee on Drugs. 'Inactive' ingredients in pharmaceutical products: update (subject review). Pediatrics 1997;99:268-278.